viewShield Therapeutics PLC

Shield Therapeutics: US commercial strategy for Accrufer and extension of cash runway

Proactive analyst Emma Ulker discusses Shield Therapeutics PLC (LON:STX) which has updated on its commercialisation plan for the US market for its oral treatment Accrufer to treat iron deficiency. 

While the company has engaged with a range of potential commercial partners for Accrufer, it is unlikely to conclude a deal in 2020 as planned, although STX remains confident that there is still room for negotiating on advantageous terms. 

Ulker talks to through the various options for STX and reiterates the company's confidence that Accrufer’s prospects remain attractive given that it is well-tolerated, has comparable efficacy to standard-of-care, and particularly given that it can be administered safely in a home setting.

Shield Therapeutics: US commercial update and cash reach extension

Quick facts: Shield Therapeutics PLC

Price: 59.5 GBX

Market: LSE
Market Cap: £69.98 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive...

Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis...

on 10/8/20

2 min read